Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Version 1 : Received: 16 November 2020 / Approved: 17 November 2020 / Online: 17 November 2020 (10:35:21 CET)

How to cite: Liberini, V.; Hüllner, M.W.; Grimaldi, S.; Finessi, M.; Thuillier, P.; Muni, A.; Pellerito, R.E.; Papotti, M.; Piovesan, A.; Arvat, E.; Deandreis, D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.. Preprints 2020, 2020110445 (doi: 10.20944/preprints202011.0445.v1). Liberini, V.; Hüllner, M.W.; Grimaldi, S.; Finessi, M.; Thuillier, P.; Muni, A.; Pellerito, R.E.; Papotti, M.; Piovesan, A.; Arvat, E.; Deandreis, D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.. Preprints 2020, 2020110445 (doi: 10.20944/preprints202011.0445.v1).

Abstract

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owing to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging, and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.

Subject Areas

Peptide Receptor Radionuclide Therapy; PRRT; 68Ga-labeled somatostatin analogue; 18F-FDG; response assessment; RECIST; SWOG; WHO; neuroendocrine tumors; NET

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.